Company intelligence / Profile preview

Hightop Biotech

Ownership: Private
Development stage: Commercial

Overview

Hightop Biotech has a broad portfolio of commercialized in vitro diagnostic products. Their HIV rapid tests have won national recognition in China for accuracy. They also offer CE-marked COVID‑19 antigen tests used internationally. No therapeutic clinical results as the company does not develop drugs.

Therapeutic areas: Infectious DiseasesOncologyGastroenterologyCardiovascularNephrologyWomen's Health
Modalities: Diagnostic reagents and kitsAnalytical instruments
Industry: Molecular Diagnostics

Beyond the preview

Go deeper on Hightop Biotech.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hightop Biotech.

Explore the full profile